The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement

English version České info

Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci employ to limit complement activation on the bacterial surface. fHbp is a leading vaccine candidate against group B Neisseria meningitidis. Novel mechanisms that meningococci employ to bind fH could undermine the efficacy of fHbp-based vaccines. We observed that fHbp deletion mutants of some meningococcal strains showed residual fH binding suggesting the presence of a second receptor for fH. Ligand overlay immunoblotting using membrane fractions from one such strain showed that fH bound to a ∼17 kD protein, identified by MALDI-TOF analysis as Neisserial surface protein A (NspA), a meningococcal vaccine candidate whose function has not been defined. Deleting nspA, in the background of fHbp deletion mutants, abrogated fH binding and mAbs against NspA blocked fH binding, confirming NspA as a fH binding molecule on intact bacteria. NspA expression levels vary among strains and expression correlated with the level of fH binding; over-expressing NspA enhanced fH binding to bacteria. Progressive truncation of the heptose (Hep) I chain of lipooligosaccharide (LOS), or sialylation of lacto-N-neotetraose LOS both increased fH binding to NspA-expressing meningococci, while expression of capsule reduced fH binding to the strains tested. Similar to fHbp, binding of NspA to fH was human-specific and occurred through fH domains 6–7. Consistent with its ability to bind fH, deleting NspA increased C3 deposition and resulted in increased complement-dependent killing. Collectively, these data identify a key complement evasion mechanism with important implications for ongoing efforts to develop meningococcal vaccines that employ fHbp as one of its components.

Vyšlo v časopise: The Meningococcal Vaccine Candidate Neisserial Surface Protein A (NspA) Binds to Factor H and Enhances Meningococcal Resistance to Complement. PLoS Pathog 6(7): e32767. doi:10.1371/journal.ppat.1001027
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1001027

Souhrn

Zdroje

1. GoldschneiderI

GotschlichEC

ArtensteinMS

1969 Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 129 1307 1326

2. FigueroaJ

AndreoniJ

DensenP

1993 Complement deficiency states and meningococcal disease. Immunol Res 12 295 311

3. FigueroaJE

DensenP

1991 Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4 359 395

4. FijenCA

KuijperEJ

te BulteMT

DahaMR

DankertJ

1999 Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28 98 105

5. RossSC

DensenP

1984 Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine (Baltimore) 63 243 273

6. JarvisGA

VedrosNA

1987 Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 55 174 180

7. UriaMJ

ZhangQ

LiY

ChanA

ExleyRM

2008 A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies. J Exp Med 205 1423 1434

8. SaECC

GriffithsNJ

VirjiM

2010 Neisseria meningitidis Opc invasin binds to the sulphated tyrosines of activated vitronectin to attach to and invade human brain endothelial cells. PLoS Pathog 6 e1000911

9. VirjiM

GriffithsNJ

Binding of Opc to vitronectin contributes to increased serum resistance of Neisseria meningitidis isolates.

van AlphenL

van der LeyP

van den DobbelsteenG

2008; Rotterdam, The Netherlands 166 167

10. JarvaH

RamS

VogelU

BlomAM

MeriS

2005 Binding of the complement inhibitor C4bp to serogroup B Neisseria meningitidis. J Immunol 174 6299 6307

11. FletcherLD

BernfieldL

BarniakV

FarleyJE

HowellA

2004 Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 72 2088 2100

12. MasignaniV

ComanducciM

GiulianiMM

BambiniS

Adu-BobieJ

2003 Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 197 789 799

13. MadicoG

WelschJA

LewisLA

McNaughtonA

PerlmanDH

2006 The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 177 501 510

14. SchneiderMC

ProsserBE

CaesarJJ

KugelbergE

LiS

2009 Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature

15. PangburnMK

SchreiberRD

Muller-EberhardHJ

1977 Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med 146 257 270

16. WeilerJM

DahaMR

AustenKF

FearonDT

1976 Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A 73 3268 3272

17. WhaleyK

RuddyS

1976 Modulation of the alternative complement pathways by beta 1 H globulin. J Exp Med 144 1147 1163

18. BeerninkPT

GranoffDM

2009 The modular architecture of meningococcal factor H-binding protein. Microbiology 155 2873 2883

19. PajonR

BeerninkPT

HarrisonLH

GranoffDM

2009 Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine

20. GranoffDM

2010 Review of group B meningococcal vaccines. Clin Infect Dis In Press

21. HammerschmidtS

MullerA

SillmannH

MuhlenhoffM

BorrowR

1996 Capsule phase variation in Neisseria meningitidis serogroup B by slipped-strand mispairing in the polysialyltransferase gene (siaD): correlation with bacterial invasion and the outbreak of meningococcal disease. Mol Microbiol 20 1211 1220

22. DeghmaneAE

GiorginiD

LarribeM

AlonsoJM

TahaMK

2002 Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol 43 1555 1564

23. ClausH

MaidenMC

MaagR

FroschM

VogelU

2002 Many carried meningococci lack the genes required for capsule synthesis and transport. Microbiology 148 1813 1819

24. ClausH

MaidenMC

WilsonDJ

McCarthyND

JolleyKA

2005 Genetic analysis of meningococci carried by children and young adults. J Infect Dis 191 1263 1271

25. YazdankhahSP

CaugantDA

2004 Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 53 821 832

26. SchneiderMC

ExleyRM

ChanH

FeaversI

KangYH

2006 Functional significance of factor H binding to Neisseria meningitidis. J Immunol 176 7566 7575

27. Biedzka-SarekM

JarvaH

HyytiainenH

MeriS

SkurnikM

2008 Characterization of complement factor H binding to Yersinia enterocolitica serotype O:3. Infect Immun 76 4100 4109

28. BerringtonAW

TanYC

SrikhantaY

KuipersB

van der LeyP

2002 Phase variation in meningococcal lipooligosaccharide biosynthesis genes. FEMS Immunol Med Microbiol 34 267 275

29. RamS

NgampasutadolJ

CoxAD

BlomAM

LewisLA

2007 Heptose I glycan substitutions on Neisseria gonorrhoeae lipooligosaccharide influence C4b-binding protein binding and serum resistance. Infect Immun

30. RamS

SharmaAK

SimpsonSD

GulatiS

McQuillenDP

1998 A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 187 743 752

31. MadicoG

NgampasutadolJ

GulatiS

VogelU

RicePA

2007 Factor H Binding and Function in Sialylated Pathogenic Neisseriae is Influenced by Gonococcal, but Not Meningococcal, Porin. J Immunol 178 4489 4497

32. MandrellRE

KimJJ

JohnCM

GibsonBW

SugaiJV

1991 Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J Bacteriol 173 2823 2832

33. KoganG

UhrinD

BrissonJR

JenningsHJ

1997 Structural basis of the Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. Carbohydr Res 298 191 199

34. TsangRS

LawDK

TsaiC

NgL

2001 Detection of the lst gene in different serogroups and LOS immunotypes of Neisseria meningitidis. FEMS Microbiol Lett 199 203 206

35. EstabrookMM

JackDL

KleinNJ

JarvisGA

2004 Mannose-binding lectin binds to two major outer membrane proteins, opacity protein and porin, of Neisseria meningitidis. J Immunol 172 3784 3792

36. DerrickJP

UrwinR

SukerJ

FeaversIM

MaidenMC

1999 Structural and evolutionary inference from molecular variation in Neisseria porins. Infect Immun 67 2406 2413

37. FeaversIM

SukerJ

McKennaAJ

HeathAB

MaidenMC

1992 Molecular analysis of the serotyping antigens of Neisseria meningitidis. Infect Immun 60 3620 3629

38. SukerJ

FeaversIM

AchtmanM

MorelliG

WangJF

1994 The porA gene in serogroup A meningococci: evolutionary stability and mechanism of genetic variation. Mol Microbiol 12 253 265

39. UrwinR

FoxAJ

MusilekM

KrizP

MaidenMC

1998 Heterogeneity of the PorB protein in serotype 22 Neisseria meningitidis. J Clin Microbiol 36 3680 3682

40. HouVC

MoeGR

RaadZ

WuorimaaT

GranoffDM

2003 Conformational epitopes recognized by protective anti-neisserial surface protein A antibodies. Infect Immun 71 6844 6849

41. MoeGR

TanS

GranoffDM

1999 Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 67 5664 5675

42. WelschJA

RamS

KoeberlingO

GranoffDM

2008 Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis 197 1053 1061

43. RipocheJ

DayAJ

HarrisTJ

SimRB

1988 The complete amino acid sequence of human complement factor H. Biochem J 249 593 602

44. ShaughnessyJ

LewisLA

JarvaH

RamS

2009 Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect Immun 77 2094 2103

45. NgampasutadolJ

RamS

GulatiS

AgarwalS

LiC

2008 Human Factor H Interacts Selectively with Neisseria gonorrhoeae and Results in Species-Specific Complement Evasion. J Immunol 180 3426 3435

46. FrieseMA

HellwageJ

JokirantaTS

MeriS

PeterHH

1999 FHL-1/reconectin and factor H: two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol Immunol 36 809 818

47. GranoffDM

WelschJA

RamS

2009 Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun 77 764 769

48. NgampasutadolJ

RamS

BlomAM

JarvaH

JerseAE

2005 Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad Sci U S A 102 17142 17147

49. BlomAM

HallstromT

RiesbeckK

2009 Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol 46 2808 2817

50. KraiczyP

WurznerR

2006 Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol Immunol 43 31 44

51. MurphyE

AndrewL

LeeKL

DiltsDA

NunezL

2009 Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 200 379 389

52. MartinD

CadieuxN

HamelJ

BrodeurBR

1997 Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185 1173 1183

53. JonesDM

BorrowR

FoxAJ

GrayS

CartwrightKA

1992 The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 13 219 224

54. MackinnonFG

BorrowR

GorringeAR

FoxAJ

JonesDM

1993 Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model. Microb Pathog 15 359 366

55. McLeod GriffissJ

BrandtBL

SaundersNB

ZollingerW

2000 Structural relationships and sialylation among meningococcal L1, L8, and L3,7 lipooligosaccharide serotypes. J Biol Chem 275 9716 9724

56. MadicoG

RamS

GetzlaffS

PrasadA

GulatiS

Sialylation of lacto-N-tetraose lipooligosaccharide in gonococci, but not meningococci, results in enhanced factor H binding: the modulatory role of gonococcal porin; 2004 September 5–September 10, 2004; Milwaukee, Wisconsin 230

57. CadieuxN

PlanteM

RiouxCR

HamelJ

BrodeurBR

1999 Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 67 4955 4959

58. EstabrookMM

JarvisGA

McLeod GriffissJ

2007 Affinity-purified human immunoglobulin G that binds a lacto-N-neotetraose-dependent lipooligosaccharide structure is bactericidal for serogroup B Neisseria meningitidis. Infect Immun 75 1025 1033

59. RamS

CoxAD

WrightJC

VogelU

GetzlaffS

2003 Neisserial lipooligosaccharide is a target for complement component C4b: Inner core phosphoethanolamine residues define C4b linkage specificity. J Biol Chem 278 50853 50862

60. SeibKL

OrienteF

Adu-BobieJ

MontanariP

FerliccaF

2010 Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine

61. SeibKL

SerrutoD

OrienteF

DelanyI

Adu-BobieJ

2009 Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect Immun 77 292 299

62. HalperinSA

LangleyJM

SmithB

WunderliP

KaufmanL

2007 Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25 450 457

63. MartinD

BrodeurBR

HamelJ

CoutureF

de AlwisU

2000 Candidate Neisseria meningitidis NspA vaccine. J Biotechnol 83 27 31

64. MoeGR

Zuno-MitchellP

HammondSN

GranoffDM

2002 Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 70 6021 6031

65. MeriS

JordensM

JarvaH

2008 Microbial complement inhibitors as vaccines. Vaccine 26 Suppl 8 I113 117

66. VogelU

ClausH

HeinzeG

FroschM

1999 Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates. Infect Immun 67 954 957

67. GulatiS

CoxA

LewisLA

MichaelFS

LiJ

2005 Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci. Infect Immun 73 7390 7397

68. LewisLA

GipsonM

HartmanK

OwnbeyT

VaughnJ

1999 Phase variation of HpuAB and HmbR, two distinct haemoglobin receptors of Neisseria meningitidis DNM2. Mol Microbiol 32 977 989

69. HouVC

KoeberlingO

WelschJA

GranoffDM

2005 Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis 192 580 590

70. GnehmHE

PeltonSI

GulatiS

RicePA

1985 Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins. J Clin Invest 75 1645 1658

71. LahmHW

LangenH

2000 Mass spectrometry: a tool for the identification of proteins separated by gels. Electrophoresis 21 2105 2114

72. McQuillenDP

GulatiS

RicePA

1994 Complement-mediated bacterial killing assays. Methods Enzymol 236 137 147

73. CuzickJ

1985 A Wilcoxon-type test for trend. Stat Med 4 87 90